ImmunoGen Competitors

Delisted . USA . 
Stock . ImmunoGen
IMGNDelisted Stock  USD 18.20  0.81  4.26%   
ImmunoGen competes with Madrigal Pharmaceuticals, TG Therapeutics, Terns Pharmaceuticals, Hepion Pharmaceuticals, and Viking Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing ImmunoGen competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ImmunoGen to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ImmunoGen competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
18.2018.2018.20
Details
Intrinsic
Valuation
LowRealHigh
12.9112.9120.02
Details
Naive
Forecast
LowNextHigh
20.3320.3320.33
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
17.9719.0320.09
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ImmunoGen. Your research has to be compared to or analyzed against ImmunoGen's peers to derive any actionable benefits. When done correctly, ImmunoGen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in ImmunoGen.

ImmunoGen Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ImmunoGen and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of ImmunoGen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ImmunoGen does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
TGTX
+ 0.83
MDGL
MCRB
+ 0.75
TERN
AXSM
+ 0.71
TGTX
PDSB
+ 0.71
MREO
PDSB
+ 0.69
VKTX
HEPA
+ 0.68
ICPT
  
High negative correlations   
PDSB
- 0.77
TGTX
MREO
- 0.73
TGTX
PDSB
- 0.66
AXSM
PDSB
- 0.61
MDGL
MREO
- 0.6
MDGL
TERN
- 0.57
TGTX

Risk-Adjusted Indicators

There is a big difference between ImmunoGen Stock performing well and ImmunoGen Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ImmunoGen's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MDGL  2.70  0.45  0.15  1.61  2.12 
(3.76)
 5.17 
(3.96)
 30.27 
ICPT  2.96 (0.91) 0.00 (0.81) 0.00 
 0.00 
 5.23 
(8.32)
 38.17 
TGTX  2.92  0.42  0.15  0.33  3.00 
(3.19)
 7.62 
(4.62)
 24.51 
TERN  3.37 (0.33) 0.00 (0.22) 0.00 
 0.00 
 6.02 
(5.96)
 34.09 
HEPA  3.78 (0.37) 0.00 (0.09) 0.00 
 0.00 
 8.06 
(8.11)
 33.54 
VKTX  3.52 (0.28) 0.00 (0.08) 0.00 
 0.00 
 6.24 
(8.05)
 34.61 
AXSM  1.78  0.11  0.03  0.33  1.87 
(2.21)
 4.10 
(3.78)
 13.67 
MCRB  4.99  0.45  0.06  1.50  5.62 
(5.99)
 10.84 
(9.78)
 28.84 
MREO  2.72 (0.48) 0.00 (0.30) 0.00 
 0.00 
 4.80 
(6.31)
 17.36 
PDSB  3.37 (0.63) 0.00 (0.24) 0.00 
 0.00 
 7.67 
(6.76)
 31.83 
All Fundamental Data

ImmunoGen Competitive Analysis

The better you understand ImmunoGen competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ImmunoGen's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ImmunoGen's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IMGN MDGL ICPT TGTX TERN HEPA VKTX AXSM MCRB MREO
 4.26 
 18.20 
ImmunoGen
 0.98 
 328.19 
Madrigal
 1.53 
 10.31 
Intercept
 0.57 
 34.80 
TGTX
 1.58 
 6.24 
Terns
 4.69 
 0.67 
Hepion
 2.88 
 52.94 
Viking
 1.44 
 98.22 
Axsome
 6.52 
 0.98 
Seres
 1.40 
 3.61 
Mereo
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Not too volatile
Slightly risky
Relatively risky
Not too volatile
Very steady
Very risky
Relatively risky
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Good
Very Weak
Very Weak
Very Weak
Modest
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Dangerous
Very Low
Average
High
About Average
Low
Quite High
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Hold
Strong Buy
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Not Rated
Hold
Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Current Ratio
4.52
2.55
3.22
4.68
23.59
8.77
11.74
2.44
2.35
7.92
Net Asset
348.94 M
640.55 M
553.71 M
329.59 M
268.52 M
18.09 M
368.49 M
588.24 M
358.6 M
66.5 M
Profit Margin
-0.26
N/A
-0.19
-0.0543
N/A
N/A
N/A
-0.92
-0.2
N/A
EBITDA
(78.46 M)
(379.97 M)
(61.7 M)
21.06 M
(102.56 M)
(49.26 M)
(100.83 M)
(224.99 M)
(94.31 M)
(26.06 M)
Operating Margin
0.23
-1.87
0.0185
0.15
N/A
N/A
N/A
-0.44
-0.34
-37.9
Current Valuation
8.2 B
6.35 B
695.84 M
5.36 B
167.04 M
7.07 M
5.15 B
4.62 B
194.11 M
478.48 M
Price To Book
15.53
9.3
44.19
28.35
1.48
2.11
6.66
51.24
7.0
7.61
Retained Earnings
(1.69 B)
(1.34 B)
(2.14 B)
(1.51 B)
(332.63 M)
(224.63 M)
(377.94 M)
(835.57 M)
(978.24 M)
(419.63 M)
Current Asset
253.11 M
363.58 K
641.69 M
71.33 M
N/A
4.82 M
15.2 M
34.76 M
207.61 M
94 K
Beta
1.17
-0.47
0.88
2.19
-0.33
1.81
0.99
1.25
2.05
0.97
Number Of Employees
277
376
341
319
66
22
30
607
233
33
Shares Outstanding
279.35 M
21.81 M
41.81 M
155.66 M
84.94 M
6.96 M
111.44 M
48.46 M
170.74 M
153.85 M
Cash Flow From Operations
(197.89 M)
(324.23 M)
(26.78 M)
(31.41 M)
(67.39 M)
(40.89 M)
(73.38 M)
(145.08 M)
(117.35 M)
(21.13 M)
Total Debt
15.24 M
117.19 M
332.67 M
110.8 M
603 K
209.02 K
1.26 M
186.37 M
213.94 M
5.95 M
Return On Equity
-0.2
-1.3
-0.64
-0.0805
-0.28
-1.9
-0.15
-1.72
-15.56
-0.48
Z Score
N/A
N/A
-3.15
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.0849
-0.52
-0.0723
-7.0E-4
-0.19
-0.93
-0.13
-0.26
-0.097
-0.24
Number Of Shares Shorted
20.61 M
4.43 M
10.19 M
28.33 M
3.98 M
64.34 K
16.99 M
7.69 M
16.24 M
5.63 M
Book Value Per Share
2.06
35.64
1.72
1.34
4.29
1.16
8.18
1.92
0.18
0.51
Current Liabilities
60.44 M
49.28 M
47.37 M
16.88 M
N/A
1.81 M
1.98 M
6.74 M
10.92 M
729 K
Total Asset
348.94 M
640.55 M
553.71 M
329.59 M
268.52 M
18.09 M
368.49 M
588.24 M
358.6 M
66.5 M
Debt To Equity
0.068
0.6
411.2
0.62
0.01
0.001
0.01
6.2
3.35
0.19
Short Ratio
3.78
7.65
2.64
7.32
3.16
0.92
2.85
15.07
7.51
6.58
Target Price
31.06
372.2
19.0
38.67
18.19
30.0
112.57
129.41
3.87
7.22
Shares Owned By Institutions
91.29
91.44
81.3
66.41
97.72
7.85
75.48
81.07
37.18
65.66
Market Capitalization
8.72 B
7.23 B
794.36 M
5.42 B
538.51 M
4.65 M
6.07 B
4.83 B
167.32 M
630.8 M
Price To Earning
-4.49
-13.96
-3.88
-4.14
N/A
-3.01
-3.17
-3.34
-4.04
6.73
Price To Earnings To Growth
N/A
N/A
-0.69
N/A
N/A
N/A
-0.03
N/A
-0.11
N/A
Price To Sales
30.33
94.11
1.6
20.46
302.64
N/A
N/A
14.27
1.32
559.3
Net Income
(73.52 M)
(373.63 M)
(174.86 M)
12.67 M
(90.21 M)
(48.93 M)
(85.89 M)
(239.24 M)
(113.72 M)
(29.47 M)
Earnings Per Share
-0.28
-25.02
-4.26
-0.1
-1.18
-4.4
-0.94
-6.58
-0.4
-0.25
Shares Owned By Insiders
0.32
8.56
3.12
9.5
0.13
0.085
5.96
16.67
13.19
1.02
Revenue
287.61 M
N/A
285.71 M
233.66 M
N/A
N/A
N/A
270.6 M
126.33 M
10 M
Working Capital
182.26 M
518.73 M
310.05 M
264.22 M
255.49 M
12.2 M
348.09 M
365.41 M
76.75 M
54.27 M
Cash And Equivalents
373.87 M
211.77 M
404.78 M
195.71 M
139.81 M
59.15 M
155.02 M
73.39 M
195.8 M
94.3 M
Cash Per Share
1.69
12.38
13.58
1.45
5.51
0.78
2.02
1.82
1.58
0.81
Gross Profit
(104.76 M)
N/A
284.73 M
2.52 M
1000 K
N/A
N/A
45.94 M
(165.79 M)
936 K
Day Typical Price
18.05
327.61
10.32
35.1
6.22
0.66
53.43
99.12
0.97
3.59
Accumulation Distribution
0.11
4374.58
0.0333
37745.19
39605.07
1122.4
49013.35
7551.52
181090.0
17612.79
Market Facilitation Index
2.07
0.0
0.35
0.0
0.0
0.0
0.0
0.0
N/A
N/A
Daily Balance Of Power
(0.39)
(0.43)
(0.46)
(0.19)
(0.28)
0.375
(0.90)
(0.51)
1.2
0.3846
Period Momentum Indicator
(0.81)
(3.26)
(0.16)
(0.20)
(0.10)
0.03
(1.57)
(1.43)
0.06
0.05
Rate Of Daily Change
0.96
0.99
0.98
0.99
0.98
1.05
0.97
0.99
1.07
1.01
Day Median Price
17.98
327.33
10.33
35.25
6.21
0.66
53.67
99.57
0.97
3.58
Price Action Indicator
(0.18)
(0.76)
(0.1)
(0.55)
(0.02)
0.025
(1.52)
(2.07)
0.045
0.06
Relative Strength Index
61.91
89.3
40.48
70.33
52.94
41.34
51.55
51.44
35.96
51.82
Coefficient Of Variation
567.23
907.53
(670.02)
595.03
(2,569)
(3,760)
(5,297)
1309.82
1318.51
(1,108)
Mean Deviation
5.45
2.7
2.96
2.92
3.37
3.78
3.52
1.78
4.99
2.72
Jensen Alpha
2.74
0.4532
(0.91)
0.4187
(0.33)
(0.37)
(0.28)
0.1091
0.4493
(0.48)
Total Risk Alpha
0.1504
(0.27)
(1.65)
(0.01)
(1.05)
(1.07)
(0.95)
(0.23)
(0.61)
(0.93)
Sortino Ratio
1.06
0.151
N/A
0.1458
N/A
N/A
N/A
0.0255
0.0552
N/A
Downside Variance
7.35
5.83
N/A
14.28
N/A
N/A
N/A
4.03
43.25
N/A
Standard Deviation
17.13
4.56
5.2
4.1
5.08
5.47
5.05
2.47
6.6
3.59
Kurtosis
57.78
13.41
14.92
1.79
7.38
6.03
4.44
2.49
0.8722
1.12
Potential Upside
8.32
5.17
5.23
7.62
6.02
8.06
6.24
4.1
10.84
4.8
Treynor Ratio
1.44
1.61
(0.81)
0.3335
(0.22)
(0.09)
(0.08)
0.3271
1.5
(0.30)
Maximum Drawdown
141.41
30.27
38.17
24.51
34.09
33.54
34.61
13.67
28.84
17.36
Variance
293.39
20.77
27.03
16.78
25.77
29.97
25.49
6.12
43.63
12.9
Market Risk Adjusted Performance
1.45
1.62
(0.80)
0.3435
(0.21)
(0.08)
(0.07)
0.3371
1.51
(0.29)
Risk Adjusted Performance
0.1443
0.0926
(0.11)
0.1366
(0.02)
(0.01)
(0.01)
0.0653
0.0668
(0.06)
Skewness
7.4
3.11
(3.01)
0.1821
1.9
1.49
0.8399
0.9524
0.3649
(0.78)
Semi Deviation
1.44
2.12
N/A
3.0
N/A
N/A
N/A
1.87
5.62
N/A
Information Ratio
0.1683
0.08
(0.18)
0.1345
(0.07)
(0.05)
(0.05)
0.0207
0.055
(0.13)
Value At Risk
(4.16)
(3.96)
(8.32)
(4.62)
(5.96)
(8.11)
(8.05)
(3.78)
(9.78)
(6.31)
Expected Short fall
(6.91)
(3.76)
N/A
(3.19)
N/A
N/A
N/A
(2.21)
(5.99)
N/A
Downside Deviation
2.71
2.41
N/A
3.78
N/A
N/A
N/A
2.01
6.58
N/A
Semi Variance
2.08
4.51
N/A
8.99
N/A
N/A
N/A
3.5
31.61
N/A

ImmunoGen Competition Performance Charts

Five steps to successful analysis of ImmunoGen Competition

ImmunoGen's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ImmunoGen in relation to its competition. ImmunoGen's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ImmunoGen in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ImmunoGen's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ImmunoGen, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ImmunoGen position

In addition to having ImmunoGen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY